Business context and reporting period
Bon Natural Life Limited filed this annual report on Form 20-F for the fiscal year ended September 30, 2022. It is an annual report, not a report for calendar 2022 Q4 alone. The company develops, manufactures, and sells natural fragrance compounds, health-supplement powder drinks, and bioactive food ingredients, primarily through operations in China. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Financial performance and position
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $29.91 million | $25.49 million | +17.3% |
| Gross profit / margin | $9.42 million / 31.5% | $7.11 million / 27.9% | Profit +32.5%; margin +3.6 percentage points |
| Operating expenses | $2.88 million | $1.71 million | +68.5% |
| Operating income / margin | $6.54 million / 21.9% | $5.40 million / 21.2% | Income +21.1% |
| Net income | $6.24 million | $4.61 million | +35.4% |
| Net income attributable to Bon Natural Life | $6.24 million | $4.59 million | +35.9% |
| Basic / diluted EPS | $0.75 / $0.74 | $0.69 / $0.68 | Higher year over year |
| Net cash from operating activities | $(0.19) million | $4.05 million | Shifted to cash use |
| Cash at year-end | $0.84 million | $1.90 million | Down $1.06 million |
Revenue mix: fragrance compounds $13.71 million (45.8%); health-supplement powder drinks $7.15 million (23.9%); and bioactive food ingredients $9.05 million (30.3%). Bioactive ingredients grew 48.5%, while fragrance sales rose 7.6% and powder-drink sales rose 7.4%.
At September 30, 2022, current assets were $14.72 million, total assets $37.26 million, current liabilities $6.65 million, total liabilities $7.16 million, and equity $30.09 million. Bank debt was approximately $4.75 million, including $4.56 million due within one year; lease obligations totaled approximately $0.58 million. Accounts receivable were $6.78 million, of which the company reported collecting about $5.0 million, or 73.5%, after year-end. Taxes payable were $1.24 million and were reported paid in October 2022.
Investing cash use was $3.06 million, principally reflecting construction spending, partly offset by redemption of short-term investments. Financing provided $2.26 million, mainly from new bank borrowings. A $2.86 million foreign-currency translation loss reduced comprehensive income to $3.39 million despite net income of $6.24 million.
Material changes versus the prior comparable period
- Revenue and net income increased, and gross margin improved from 27.9% to 31.5%, supported by higher selling prices, product mix, and bioactive-ingredient volume.
- Fragrance-compound sales volume fell 15.1% amid wet-weather-related clary sage shortages and COVID-related logistics disruption. Average selling prices increased across all three product categories.
- Operating expenses rose 68.5%; general and administrative expenses increased 69.2%, and R&D expenses increased 70.5%.
- Government subsidies recognized as other income rose to $1.31 million from $0.45 million and materially contributed to the increase in other income.
- Operating cash flow fell from $4.05 million provided to $0.19 million used, including cash impacts from tax payments, higher receivables, and lower deferred revenue.
- Total liabilities declined to $7.16 million from $9.88 million, while cash fell and short-term borrowing increased.
Outlook, risks, contingencies, and unusual items
- Management stated a target of at least 30% compound annual growth for the raw-materials and ingredients business over the next two to three years. This is a management target, not a guarantee; the filing gives no consolidated revenue or earnings guidance.
- Tongchuan manufacturing facilities entered production in December 2022. The Yumen plant was expected to be completed in May 2023. Remaining disclosed construction commitments were $728,470; management also cited about $1.2 million of related working-capital needs.
- Management estimated expansion capital needs at approximately $40 million and warned that funding may not be available on acceptable terms. It said cash, the January 2023 private placement proceeds, and available credit would fund needs for at least 12 months.
- On January 17, 2023, the company reported a private offering of 2.75 million shares at $0.80 per share, raising $2.2 million, plus warrants for the same number of shares at $0.88, exercisable for 24 months. This materially increases potential dilution. The filing’s subsequent-event note contains an inconsistent reference to January 17, 2022; verify the date and terms against the related filing.
- COVID-19 resurgence, supply interruptions, weather-related raw-material availability, supplier concentration, and customer concentration remain risks. Three customers represented 74.8% of FY2022 revenue; four suppliers represented 62.2% of purchases.
- Products have not been clinically proven by the company to be safe or effective for treating or preventing health conditions; management cautions that product claims are not regulatory approval. Food safety, product liability, licensing, and factory compliance risks are disclosed.
- The company disclosed material weaknesses in internal control over financial reporting, principally insufficient accounting staff and U.S. GAAP/SEC reporting expertise. Management considered controls ineffective at September 30, 2022 and said remediation was incomplete. The financial-statement auditor issued an unqualified opinion but did not audit internal-control effectiveness.
- Other disclosed exposures include PRC regulatory and cross-border cash-transfer uncertainty; possible limits on dividends from PRC subsidiaries; foreign-exchange risk (the RMB depreciated 10.2% against the U.S. dollar during FY2022); tax and labor-compliance matters; unregistered property leases; and construction-permit issues at a leased site. The company reported no material legal proceedings and no off-balance-sheet arrangements.
- The company reported no expected cash dividends in the foreseeable future. A prior VIE structure was terminated effective November 2021; the associated value-added telecommunications license was revoked, and the company said it was exploring other online-sales options.
Important facts for investors to verify
- Whether subsequent receivable collections continued and whether customer and supplier concentration has changed.
- Operating cash generation, working-capital needs, bank-loan renewals, and the availability and terms of unused credit facilities.
- Completion, costs, and operating contribution of the Tongchuan and Yumen plants, including any additional capital needs.
- The actual receipt and use of private-placement proceeds, warrant terms, current shares outstanding, and resulting dilution.
- Progress in remediating internal-control material weaknesses and the status of the company’s accounting and SEC-reporting resources.
- Renewal of the HNTE tax qualification, settlement of tax obligations, and any PRC approvals or filings that could affect operations, financing, or repatriation of funds.
- Support for management’s 30% business-line growth target and the contribution of government subsidies to earnings.